Abstract: A spectrally encoded fluorescence imaging system includes a multi-wavelength excitation light source emitting excitation light for illuminating a sample, optical components for introducing spectral encoding to focus different wavelengths of the excitation light at different positions in the sample to generate fluorescence at different, spatial positions, and band-shifting florescence imaging probes exhibiting excitation-dependent emission band, causing the fluorescence generated at different spatial positions to exhibit different band shifts, such that image information is encoded in the band-shifted fluorescence spectrums for parallel detection by a spectrometer or arrayed detectors operable to resolve different wavelengths.

Abstract: A spectrally encoded fluorescence imaging system includes a multi-wavelength excitation light source emitting excitation light for illuminating a sample, optical components for introducing spectral encoding to focus different wavelengths of the excitation light at different positions in the sample to generate fluorescence at different, spatial positions, and band-shifting florescence imaging probes exhibiting excitation-dependent emission band, causing the fluorescence generated at different spatial positions to exhibit different band shifts, such that image information is encoded in the band-shifted fluorescence spectrums for parallel detection by a spectrometer or arrayed detectors operable to resolve different wavelengths.

Abstract: A medicament for inhibiting platelet aggregation, comprising atractylenolide compound or its derivatives, wherein the said atractylenolide compound has the following structural formula shown in formula (I), wherein R1 represents H or C1-C10 linear or branched alkyl, R2 represents H or C1-C10 linear or branched alkyl, and R3 represents H or hydroxyl. Use of atractylenolide compound shown in formula (I) or its derivatives in the manufacture of a medicament for inhibiting platelet aggregation. The medicament for inhibiting platelet aggregation of the present application has good efficacy without toxic-and-side effect, lower tendency of tolerance, convenient to take and applicable for preventing or treating diseases caused by high platelet aggregation rate.

Abstract: A medicament for inhibiting platelet aggregation, comprising atractylenolide compound or its derivatives, wherein the said atractylenolide compound has the following structural formula shown in formula (I), wherein R1 represents H or C1-C10 linear or branched alkyl, R2 represents H or C1-C10 linear or branched alkyl, and R3 represents H or hydroxyl. Use of atractylenolide compound shown in formula (I) or its derivatives in the manufacture of a medicament for inhibiting platelet aggregation. The medicament for inhibiting platelet aggregation of the present application has good efficacy without toxic-and-side effect, lower tendency of tolerance, convenient to take and applicable for preventing or treating diseases caused by high platelet aggregation rate.